Market Research Logo

Liver Fibrosis - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Liver Fibrosis Overview
Therapeutics Development
Pipeline Products for Liver Fibrosis - Overview
Pipeline Products for Liver Fibrosis - Comparative Analysis
Liver Fibrosis - Therapeutics under Development by Companies
Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes
Liver Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Liver Fibrosis - Products under Development by Companies
Liver Fibrosis - Products under Investigation by Universities/Institutes
Liver Fibrosis - Companies Involved in Therapeutics Development
Advinus Therapeutics Ltd.
AiCuris GmbH & Co. KG
Angion Biomedica Corp.
Bioneer Corporation
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Celgene Corporation
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Evotec AG
FibroGen, Inc.
Galectin Therapeutics, Inc.
Genfit SA
Gilead Sciences, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Intercept Pharmaceuticals, Inc.
Isarna Therapeutics GmbH
KineMed, Inc.
LG Life Science LTD.
Nitto Denko Corporation
Pfizer Inc.
Pharmaxis Limited
Promedior, Inc.
Promethera Biosciences S.A.
ProMetic Life Sciences Inc.
RuiYi Inc.
RXi Pharmaceuticals Corporation
SciFluor Life Sciences, LLC
TCM Biotech International Corp
Vascular Biogenics Ltd.
Virobay Inc.
XTuit Pharmaceuticals, Inc.
Liver Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AIC-649 - Drug Profile
ANG-3281 - Drug Profile
ANG-4011 - Drug Profile
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
BOT-162 - Drug Profile
CC-539 - Drug Profile
CC-90001 - Drug Profile
CIGB-500 - Drug Profile
CPI-43132 - Drug Profile
CT-140 - Drug Profile
DB-036 - Drug Profile
DCBBO-1202 - Drug Profile
disitertide - Drug Profile
Drugs for Tissue Fibrosis - Drug Profile
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis - Drug Profile
elafibranor - Drug Profile
F-351 - Drug Profile
FG-3019 - Drug Profile
GM-CT-01 - Drug Profile
GRMD-02 - Drug Profile
HEC-00000585 - Drug Profile
HepaStem - Drug Profile
INT-767 - Drug Profile
ISTH-0047 - Drug Profile
KW-1 - Drug Profile
LC-280126 - Drug Profile
melittin - Drug Profile
MOR-8457 - Drug Profile
ND-L02s0201 - Drug Profile
noscapine - Drug Profile
NPLC-0393 - Drug Profile
P-17 - Drug Profile
PBI-4050 - Drug Profile
PRM-151 - Drug Profile
PXS-4728A - Drug Profile
PXS-5033A - Drug Profile
Recombinant Enzyme to Replace MMP-9 for Liver Fibrosis and Pulmonary Fibrosis - Drug Profile
RXI-209 - Drug Profile
RYI-018 - Drug Profile
selonsertib - Drug Profile
simtuzumab - Drug Profile
Small Molecule for Liver Fibrosis - Drug Profile
Small Molecule for Liver Fibrosis - Drug Profile
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile
Small Molecules for Fibrosis - Drug Profile
Small Molecules to Antagonize Receptor Tyrosine Kinase for Liver Fibrosis - Drug Profile
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology - Drug Profile
TCM-808FB - Drug Profile
VB-201 - Drug Profile
VBY-376 - Drug Profile
VBY-825 - Drug Profile
Liver Fibrosis - Recent Pipeline Updates
Liver Fibrosis - Dormant Projects
Liver Fibrosis - Discontinued Products
Liver Fibrosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Liver Fibrosis, H2 2015
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd., H2 2015
Liver Fibrosis - Pipeline by AiCuris GmbH & Co. KG, H2 2015
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2015
Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2015
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015
Liver Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Liver Fibrosis - Pipeline by Celgene Corporation, H2 2015
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015
Liver Fibrosis - Pipeline by Evotec AG, H2 2015
Liver Fibrosis - Pipeline by FibroGen, Inc., H2 2015
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Liver Fibrosis - Pipeline by Genfit SA, H2 2015
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2015
Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2015
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
Liver Fibrosis - Pipeline by KineMed, Inc., H2 2015
Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2015
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2015
Liver Fibrosis - Pipeline by Pfizer Inc., H2 2015
Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2015
Liver Fibrosis - Pipeline by Promedior, Inc., H2 2015
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2015
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015
Liver Fibrosis - Pipeline by RuiYi Inc., H2 2015
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Liver Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2015
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2015
Liver Fibrosis - Pipeline by Virobay Inc., H2 2015
Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Liver Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Liver Fibrosis - Dormant Projects, H2 2015
Liver Fibrosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Liver Fibrosis, H2 2015
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Liver Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Liver Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Liver Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Liver Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Liver Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;